Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial involved 14 people in total — 8 in the "Buparid" group (Treatment A) and 6 in the "Budes" group (Treatment B). All 14 participants completed the trial. The study was measuring changes in inflammation of the nasal passages and sinuses, using a scoring system called the Lund-Mackay score (based on MRI scans), where a score of 0 means no impairment and 24 means the most severe impairment. It also looked at side effects, quality of life, and nasal airflow. The reported data shows that, for the primary measure — change in nasal and sinus inflammation — the Buparid group's average score went down by 2 points, while the Budes group's average score went down by 0.8 points. A lower (more negative) change means the score reduced from where it started. For the secondary measure of side effects, 5 out of 8 participants in the Buparid group and 4 out of 6 in the Budes group experienced at least one adverse event (an unwanted or unexpected health event noticed during the trial). For quality of life, measured using a 22-question survey (scored 0–110, where higher means more difficulty), the reported average change from the start of the trial to 24 weeks was an increase of 23.6 points in the Buparid group and 14.4 points in the Budes group — noting that a higher number here indicates more reported difficulty. For nasal airflow, measured at two time points (4 and 8 weeks), the reported figures were not described in a way that allows straightforward comparison without additional context, but the raw values ranged from 574 to 755 ml/sec across both groups and time points. It is worth noting that this was a very small trial, and some details — such as what the scores were at the start of the trial — were not fully reported in the structured data, so the full picture of the changes cannot be described here. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Chronic Rhinosinusitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with chronic rhinosinusitis (long-term sinus inflammation) with nasal polyps graded as level I, II, or III
- You have a minimum level of airflow measurable through each side of your nose separately (confirmed by a specific breathing test called PNIF showing more than 7 litres per minute on each side)
- You are willing and able to sign a written consent form
- You are male or female and are 18 years of age or older
- You are able to receive treatment applied inside the nose without any restrictions
- You are able to understand the purpose and risks of the clinical trial
- If you are a woman who could become pregnant, you must have a negative urine pregnancy test before the study treatment starts
- You have correctly filled in a diary during the initial lead-in phase of the trial
Who may not be able to join:
- You have cystic fibrosis
- You have nasal polyps at the most severe grade (grade IV)
- You have previously had surgery on your sinuses or nose, unless it was only a simple polyp removal
- You have a condition affecting the tiny hair-like structures in your airways called cilia (confirm with trial site)
- You are currently pregnant or breastfeeding
- You appear to have an active infection in your upper airways (such as a cold or sinus infection)
- You have taken part in another clinical drug trial within the last 4 weeks
- You have a current problem with drug or alcohol misuse
- You have a serious, advanced-stage cancer
- You have a known allergy or sensitivity to a medication called Budesonide
- You have taken steroid tablets or capsules by mouth within the last 4 weeks
- You get nosebleeds frequently (more than twice a month)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change of Inflammation of the Nasal Mucosa and Paranasal Sinus
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.